MEDRAD unveils new CV division after merger with Possis

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

WASHINGTON, D.C.—The merger of MEDRAD and Possis Medical has resulted in a new cardiovascular products division named MEDRAD Interventional/Possis. The company is exhibiting this week at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

The new division combines several known products including the AngioJet Thrombectomy System, the Avanta Fluid Management Injector System, the Mark V ProVis Angiographic Injection System and the Fetch Aspiration Catheter, among others.

The new interventional division of MEDRAD increases the international reach of the former Possis Medical product portfolio with sales operations in more than 30 countries.

Possis brings its interventional sales team to the new division, which significantly expands the market presence for the MEDRAD interventional products in the U.S., according to MEDRAD.

“The name and brand tells the purpose and show the heritage of our new division,” said John Friel, president and CEO of MEDRAD.

Friel commented that Possis Medical and MEDRAD’s former cardiovascular business unit complement each other well and “the resulting team is experienced and well positioned to serve the needs of interventional cardiology, interventional radiology and vascular surgery.”